Viking Therapeutics (VKTX) closed at $28.44 on November 11, 2026, down 0.8% from the previous close, on volume of 2,507,534 shares (30-day average 4,740,052).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | 10 Leg Put Combo with Ratio | 16-Oct-2630.5[428x] : 31[428x] : 31.5[68x] : 32[237x] : 32.5[916x] : 33[202x] : 33.5[274x] : 34[879x] : 35[202x] : 37.5[68x] P | 3,702 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek 2026
PRNewswire (Mon, 9-Nov 7:05 AM ET)
Viking Therapeutics Lines Up Five Investor Conferences as VK2735 Advances in Phase 3 Obesity Studies
Market Chameleon (Wed, 4-Nov 3:00 AM ET)
Viking Therapeutics to Participate at Upcoming Investor Conferences
PRNewswire (Tue, 3-Nov 4:30 PM ET)
Peptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
Globe Newswire (Tue, 3-Nov 9:00 AM ET)
Market Chameleon (Thu, 29-Oct 3:59 AM ET)
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PRNewswire (Wed, 28-Oct 4:05 PM ET)
Viking Therapeutics sets Oct. 28 earnings date with Phase 3 obesity program VK2735 in focus
Market Chameleon (Thu, 22-Oct 4:29 AM ET)
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
PRNewswire (Wed, 21-Oct 4:06 PM ET)
PRNewswire (Wed, 14-Oct 7:05 AM ET)
PRNewswire (Tue, 6-Oct 7:07 AM ET)
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Viking Therapeutics trades on the NASDAQ stock market under the symbol VKTX.
As of November 12, 2026, VKTX stock price declined to $28.20 with 996,236 million shares trading.
VKTX has a beta of 1.16, meaning it tends to be more sensitive to market movements. VKTX has a correlation of 0.06 to the broad based SPY ETF.
VKTX has a market cap of $3.60 billion. This is considered a Mid Cap stock.
In the last 3 years, VKTX traded as high as $99.41 and as low as $9.49.
The top ETF exchange traded funds that VKTX belongs to (by Net Assets): VTI, XBI, VB, VBK, VXF.
VKTX has underperformed the market in the last year with a return of -30.5%, while the SPY ETF gained +12.4%. In the last 3 month period, VKTX fell short of the market, returning -16.6%, while SPY returned -1.1%. However, in the most recent 2 weeks VKTX has outperformed the stock market by returning +11.2%, while SPY returned -1.5%.
VKTX support price is $27.23 and resistance is $29.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VKTX shares will trade within this expected range on the day.
